Anzeige
Mehr »
Dienstag, 05.08.2025 - Börsentäglich über 12.000 News
Der nächste HYPE beginnt: Angriff im Dogecoin- & Litecoin-Bereich nach der Spitze
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
277 Leser
Artikel bewerten:
(0)

iNewswire: POMS Announces the Release of POMSnet R500.3 With HTML5 User Interface and Touch Screen-Enabled, Web-Based Manufacturing Execution System

WASHINGTON, DC / ACCESSWIRE / December 5, 2019 / Washington, D.C.-based POMS Corporation announces the next major release of POMSnet, R500.3. POMSnet R500.3 is an industry-leading, cloud-enabled, HTML5 manufacturing execution system. This release provides enhanced user experience by leveraging HTML5 technologies for the most comprehensive, commercial, off-the-shelf (COTS) MES product available to the life sciences industry. POMSnet MES enables life science manufacturers (i.e., pharma, biotech, medical device, cell/gene therapy) to implement regulatory-compliant, paperless manufacturing workflows for batch records and product release. POMSnet R500.3 includes a user interface style update with responsive actions, including touch screen enabled hand gestures, zooming, and finger scrolling. Browser compatibility is greatly increased and now allows HTML5-enabled browser selection to run the web-based application. Mobile device delivery and responsive technology fit POMSnet R500.3 onto any mobile device screen.

POMSnet R500.3 HTML5 User Interface Screen Images

POMS Corp. Release New HTML5 Version of POMSnet Manufacturing Execution System for Life Science Industry

In addition to the full HTML5 update of the product, POMS has also added other significant features and enhancements such as the following:

  • Dispensing Dashboard displays the overall batch details (i.e., order, batch, product, lot, status, dispense times and exceptions) and dispenses details (i.e., dispense details for each Bill of Material line item, such as containers dispensed, quantities, times, locations and scales).
  • Query Manager allows users to define and create any database query report against the POMS database. All the data is exposed for user query and reporting. This will also allow POMS to continue to add standard product reports/queries in ongoing releases based on customer requests. This release provided 70 standard out-of-the-box query reports.
  • An enhanced version of Specification Manager to support faster recipe batch record management and changes. In addition, with the HTML5 updates, batch record recipes will now support advanced instructional text such as links to pictures, videos, and advanced text formatted instructions. Recipe procedure function charts now also support graphic objects with configurable dynamic behaviors.

Life science manufacturers are regulated by regulatory authorities and current good manufacturing practices cGMP in the production process of pharmaceutical and biotech medicines and required to follow safety procedures. Companies have traditionally sought paper forms to document the production process recipe and specifications followed during manufacturing. With POMSnet R500.3 the manufacturing workflow can be implemented, monitored, and controlled by the manufacturing execution system to ensure regulatory guidelines are followed, best practices are implemented, and cGMP is enforced.

POMS Corporation, based out of Washington, D.C., is an MES software provider that counts five of the world's 10 largest pharmaceutical companies among its clients.

"Short term, our goal is to get this technology out in front of our customers so they can recognize the benefits quickly," said Patrick Nazzaro, General Manager at POMS. "Longer term, the technology offers us the capability to do more rapid agile development and release the extensive, feature-rich functionality the industry demands."

What pharmaceutical experts are saying about POMSnet R500.3 on LinkedIn

POMSnet R500.3 release is available now by contacting POMS Corporation.

About POMS Corporation

A Washington, D.C.-based provider of Manufacturing Execution System software for regulated life science companies. POMS provides web-based and cloud-based MES solutions for life science manufacturers ensuring FDA compliance and 21 CFR Part 11 electronic signatures for electronic batch records. POMS Corporation is a company in the Perseus Operating Group with the parent company Constellation Software Inc. headquartered in Toronto, Canada, and traded on the Toronto Stock exchange with $3.1 billion revenue and 16,000 employees worldwide.

Media Contacts
Darrell Tanner
POMS
703-574-9900
Darrell.tanner@poms.com

SOURCE: POMS Corporation



View source version on accesswire.com:
https://www.accesswire.com/569202/POMS-Announces-the-Release-of-POMSnet-R5003-With-HTML5-User-Interface-and-Touch-Screen-Enabled-Web-Based-Manufacturing-Execution-System

© 2019 ACCESS Newswire
Zeitenwende! 3 Uranaktien vor der Neubewertung
Ende Mai leitete US-Präsident Donald Trump mit der Unterzeichnung mehrerer Dekrete eine weitreichende Wende in der amerikanischen Energiepolitik ein. Im Fokus: der beschleunigte Ausbau der Kernenergie.

Mit einem umfassenden Maßnahmenpaket sollen Genehmigungsprozesse reformiert, kleinere Reaktoren gefördert und der Anteil von Atomstrom in den USA massiv gesteigert werden. Auslöser ist der explodierende Energiebedarf durch KI-Rechenzentren, der eine stabile, CO₂-arme Grundlastversorgung zwingend notwendig macht.

In unserem kostenlosen Spezialreport erfahren Sie, welche 3 Unternehmen jetzt im Zentrum dieser energiepolitischen Neuausrichtung stehen, und wer vom kommenden Boom der Nuklearindustrie besonders profitieren könnte.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders von der Energiewende in den USA profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.